Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Craft Emerald (also known as Demecan Craft Emerald 27:01) is an unirradiated, indica-dominant hybrid medical cannabis flower imported from Canada and distributed in Germany by DEMECAN. Cultivated by Canary RX, Craft Emerald is derived from the 'Governmint Oasis' cultivar, which is a genetic cross between GMO (Garlic Cookies) and Gush Mints. The flower features a high tetrahydrocannabinol (THC) content of approximately 25.1% to 27% and a low cannabidiol (CBD) content of less than 1%. Its terpene profile is dominated by beta-caryophyllene, limonene, alpha-humulene, and beta-myrcene, contributing to a sweet, minty, and earthy aroma. Craft Emerald is prescribed as an inhalation therapy for patients suffering from chronic pain, sleep disorders (insomnia), depression, and appetite loss.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Craft Emerald.